LXEO Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. (LXEO) is expected to report earnings on November 11, 2026, after the market close. The consensus earnings estimate is a loss of $0.34 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.0% since its last earnings release on August 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Lexeo Therapeutics, Inc.
Lexeo Therapeutics is a clinical-stage genetic medicine company which defined cardiovascular diseases and APOE4-associated Alzheimer's disease are treated. Lexeo Therapeutics is based in New York City.
Sector
Healthcare
Industry
Biotechnology